Onkologie. 2017:11(5):220-223 | DOI: 10.36290/xon.2017.041

The role of hyperthermic intraperitoneal chemotherapy in the treatment of advanced and recurrent ovarian cancer

Richard Feranec, Josef Chovanec
Oddělení gynekologické onkologie, Klinika operační onkologie MOU a LF Masarykovy univerzity Brno

Ovarian cancer is the most common cause of death in gynaecological malignancies. The disease is diagnosed in advanced stagewith peritoneal carcinomatosis in most cases. The treatment is based on primary cytoreductive surgery followed by chemotherapy.Benefit of intraperitoneal chemotherapy in frontline treatment has been confirmed. Currently, the increasing interest inpotential benefit of radical cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC) in frontline ovariancancer treatment and therapy of recurrencies is noted. The results of recent trials are limited and heterogenous. Results of ongoingphase III prospective trials are expected.

Keywords: ovarian cancer, HIPEC

Published: November 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Feranec R, Chovanec J. The role of hyperthermic intraperitoneal chemotherapy in the treatment of advanced and recurrent ovarian cancer. Onkologie. 2017;11(5):220-223. doi: 10.36290/xon.2017.041.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Dušek L, Mužík J, Kubásek M, et al. SVOD: Epidemiologie zhoubných nádorů v České republice [online]. Masarykova univerzita 2005, dostupný z WWW: http://www.svod.cz. Verze 7.0 [2007], ISSN 1802-8861.
    2. Bakrin N, Bereder JM, Decullier E, et al. Peritoneal carcinomtosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol 2013; 39(12): 1435-1443. Go to original source... Go to PubMed...
    3. Rosen B, Laframboise S, Ferguson S, et al. The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer. Gynecol Oncol 2014; 134(3): 462-467. Go to original source... Go to PubMed...
    4. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cysplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996; 335: 1950-1955. Go to original source... Go to PubMed...
    5. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354: 34-43. Go to original source... Go to PubMed...
    6. Markman M, Bundy BN, ALberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern kooperative Oncology group. J Clin Oncol 2001; 19: 1001-1007. Go to original source... Go to PubMed...
    7. Landrum LM, Jawa J, Mathews CA, et al. Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study: Gynecol Oncol 2013; 130(1): 8-12. Go to original source... Go to PubMed...
    8. Tewari J, Jawa J, Salani R, et al. Long-term survival advantage of intraperitoneal chemotherapy treatment in advanced ovarian cancer: an analysis of a Gynecologic Oncology Group ancillary data study. Gynecol Oncol 2013; 130(1): 4. Go to original source...
    9. Harter P, et al. Surgery for reccurent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications and prognostic value of peritoneal carcinomatosis. Ann Surg Oncol. 2009; 16(5): 1324-1330. Go to original source... Go to PubMed...
    10. Harter P, et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the multicenter intergroup study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO Austria, and MITO. Int J Gynecol Cancer, 2011; 21(2): 289-295. Go to original source... Go to PubMed...
    11. Chi DS, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer, 2006; 109(9): 1933-1939. Go to original source...
    12. Bakrin N, Cotte E, Golfier F, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and reccurent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients. Ann Surg Oncol 2012; 19: 4052-4058. Go to original source...
    13. Spiliotis J, Vaxevanidou A, Sergouniotis F, et al. The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in ther management of recurrent advanced ovarian cancer: a prospective study. J BUON 2011; 16(1): 74-79. Go to PubMed...
    14. Fagotti A, Constantini B, Petrillo M, et al. Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case control study on survival in patients with two year follow-up. Gynecol. Oncol. 2012; 127(3): 502-505. Go to original source...
    15. Brown CK, Williams S, McNutt L, et al. Cytoreductive surgery (CRS) and HIPEC in recurrent platinum-resistant ovarian cancer. Gynecol. Oncol. 2015; 137: 114. Go to original source...
    16. Classe JM, Glehen O, Decullier E, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for first relapse of ovarian cancer. Anticancer Res. 2015; 35(9): 4997-5005.
    17. Hotouras A, Desai D, Bhan C, et al. Heated intraperitoneal chemotherapy (HIPEC) for patients with recurrent ovarian cancer: A systematic literature review. Int. J. Gynecol. Cancer. 2016; 26(4): 661-670. Go to original source...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.